Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Arthritis Rheum. 2012 Jul;64(7):2289–2299. doi: 10.1002/art.34411

Figure 4. ADAMTS5 and MMP10 expression in clonal cell lines treated with pathway inhibitors or LiCl.

Figure 4

(A) ADAMTS5 and MMP10 expression measured by real time RT-PCR in one empty vector clone (vector) and one WISP3/CCN6 clone (WISP3) incubated in low serum (0.5%) growth medium (control) or 10μM U0126 (U0126, a MEK1/2 inhibitor), 10μM SB202190 (SB, a p38 MAPK inhibitor) or 5μg/ml BMS 354451 (BMS, a IκB kinase inhibitor) in low serum (0.5%) growth medium for 6.5h. Each bar is the mean of the fold change in three wells ± s.e.m compared to control cells stably over-expressing the empty vector in control conditions. (B) ADAMTS5 and MMP10 expression in three empty vector clones (vector) and three WISP3/CCN6 clones (WISP3) incubated in 40mM NaCl (as an osmolarity control) or 40mM LiCl for 24h. Each bar is the mean of the fold change in three clones ± s.e.m compared to the clones stably over-expressing the empty vector in NaCl. MMP10 and ADAMTS5 expression is normalised to 18S. *, **, *** = a significant difference where P is ≤ 0.05, 0.01 and 0.001 respectively.